Memory loss. Confusion. Loss of motor skills. Inability to reason logically.
And ultimately death.
This scenario describes the situation for 50 million people worldwide and counting.
They have Alzheimer’s disease.
It is a debilitating brain disorder that is now considered to be the greatest global health care challenge of the 21st century.
Existing challenges in the treatment of Alzheimer’s disease include the following:
#1 The Blood-Brain-Barrier.
Mother nature created specialized cells which surround the central nervous system, protecting it from all foreign substances. This includes making it extremely difficult for medications to cross into the brain.
#2 Hepatic First-Pass Effect.
Oral medications first get partially metabolized by the liver. This makes drugs less bioavailable to their target site.
#3 Treatment requires daily medication.
This is a huge burden for Alzheimer’s patients, who experience forgetfulness.
#4 Targeting drug delivery to the Alzheimer’s affected area of the brain.
#5 Patients are often non-compliant with medications because they are confused.
Our company will solve ALL of these challenges using nano biotechnology.
Total Achievable Market = Global Alzheimer’s Disease Pharmaceutical Industry
2020: $5.9 Billion, Compound Annual Growth Rate 10.5%
2023: $13.3 Billion
2030: $50 Billion
Serviceable Achievable Market = Global Alzheimer’s Population
2020: 50 Million patients
2023: 57 Million patients
2030: 70 Million patients
· 1 in 10 persons > 65 years old, 1 in 3 persons > 85 years old
· 14% increase in cases annually
Our company has developed a drug delivery system to specifically treat Alzheimer’s disease.
We call it nano Alzheimer’s Drug Entry Pharmaceutical Target (nano-ADEPT).
The drug design is on the nano scale, which is on the order of 1-100 billionths of a meter. For reference, 1 nano = 3 atoms long.
These Polymeric Nanoparticles will be carriers for the Alzheimer’s drugs already on the market. The complex will be administered by convenient monthly injection, bypass liver metabolism, cross the blood brain barrier efficiently, and supply controlled release of drug at the target areas in the brain.
nano-ADEPT will fulfill all the unmet needs in Alzheimer’s treatment.
It will provide superior treatment over current oral and transdermal patch medication options.
Much of the work that is being done in nano biotechnology is academic and at the government level.
We will use an already established mouse model of Alzheimer’s Disease for pre-clinical trials.
We have identified the intellectual property from the U.S. Department of Energy and the public sector.
In collaboration with the following academic institutions, we have obtained a patent license agreement for the method to manufacture our nanoparticle delivery system complex.
nano-ADEPT will be customized for targeted delivery to the Alzheimer’s affected area of the brain.
We will obtain Amyloid beta protein and Tau antibodies from an antibody database, then attach these to the surface of our nano carrier.
We will utilize an international patent to achieve nano-carrier controllable and sustained drug release over several weeks at a time.
Our unique value proposition is at the cutting edge.
The proprietary technology exists.
Our company proposes 3 nanodrug carrier designs, shown below as 3D rendered models.
They are nanospheres with Alzheimer’s drug loaded in variable sites. The surface is modified with antibodies for amyloid beta and tau proteins to achieve targeted drug delivery.
Our market survey was segmented into 2 target audiences.
First, we polled 542 Adult Neurologists and Geriatric Medicine Physicians from the following Academic Centers and Community Hospitals.
Second, we interviewed executives from the following pharmaceutical companies.
Results validate our company’s purpose and targets.
Of the 119 responses received, the majority of doctors feel that the top 3 unmet needs in Alzheimer’s treatment are targeted drug delivery, drug bioavailability, and optimizing drug release.
Almost all predict that the number of Alzheimer’s patients in their practice will increase over the next decade.
And 92% of these physicians see promise in nano-ADEPT.
Our target partners are the 5 pharmaceutical companies that manufacture Alzheimer’s medications.
With our unique nano biotechnology, we will re-formulate existing Alzheimer’s drugs, providing the nano carrier for their drug delivery.
Years 1 - 2: Complete proof of principle, utilizing capital from seed investors.
Years 3 - 6: Research & Development, utilizing capital from Big Pharma companies.
Years 7 - 10: Clinical Trials, receive milestone payments from Big Pharma companies.
Jaiden Martinez
CEO
Jaiden@nanoNeuroTherapeutics.org